Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I/II study on the safety and pharmacokinetics of FIT039 administered by single adhesive skin patch application for the cases of human papillomavirus verrucae

Trial Profile

Phase I/II study on the safety and pharmacokinetics of FIT039 administered by single adhesive skin patch application for the cases of human papillomavirus verrucae

Completed
Phase of Trial: Phase I/II

Latest Information Update: 04 Oct 2018

At a glance

  • Drugs FIT 039 (Primary)
  • Indications Warts
  • Focus Adverse reactions
  • Most Recent Events

    • 04 Oct 2018 Results published in the Clinical Drug Investigation
    • 19 May 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top